Thread by @SeguraJuanJ

Finally, #Prodige7 results are out at @TheLancetOncol!

This is a giant step forward building evidence on Peritoneal Metastases of CRC origin.

French groups have to be congratulated for this outstanding work.

@RENAPE_Network & @GroupeUNICANCER-GI

doi.org/10.1016/S1470-…

#Prodige7 is the 1st prospective study to report these excellent survival outcomes in PM of CRC origin:
-Median OS: 41'2-41-7 months
-1y OS: 86'9-88'3%
-5y OS: 36'7-39.4%
Relapse-free survival is astonishing too:
-Median RFS: 11'1-13'1 months
-1y RFS: 46'1-59%
-5y RFS: 13'1-14'8%

Although there is no difference regarding OS, RFS or PFS between cytoreductive surgery alone VS Oxaliplatin-based HIPEC.

There is room for hope and new research regarding PCI 11-15 where HIPEC does better in OS and RFS than surgery alone.

This is a really good study. If it were designed today probably a 30 min oxaliplatin-based HIPEC wouldn't have been used or maybe PCI>15 would have been excluded.

But the truth is these conclusions are perfect and this study give us plenty of light.

So, these are the main results that will impact our clinical activity:

- Oxaliplatin-based HIPEC doesn't work

- Cytoreductive surgery in specialized centers does work, A LOT!

- RCT in #HIPEC are feasible, we need to follow this path

- #HIPEC might have an impact in PCI11-15

Finally, I give you my own interpretation of #Prodige7.

I hope you like it 😉